Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer

Table 1 Baseline comparison between the inetetamab combined with S-1 plus oxaliplatin group and the trastuzumab combined with S-1 plus oxaliplatin group

Clinical characteristics	Inetetamab group (n = 18)	Trastuzumab group (n = 19)	χ2/t value	P value
Sex, n (%)			0.073	0.787
Male	14 (77.8)	13 (68.4)
Female	4 (22.2)	6 (31.6)
Age, mean ± SD	64.28 ± 9.19	66.47 ± 6.64	0.836	0.068
Clinical stage, n (%)			0.004	0.948
Stage III	3 (16.7)	2 (10.5)
Stage IV	15 (83.3)	17 (89.5)
HER2 status, n (%)			0.140	0.709
IHC3+	16 (88.9)	15 (78.9)
IHC2+, FISH+	2 (11.1)	4 (21.1)
Surgical history, n (%)			0.667	0.414
Yes	7 (38.9)	5 (26.3)
No	11 (61.1)	14 (73.7)
ECOG score, n (%)			0.016	0.898
0	11 (61.1)	12 (63.2)
1	7 (38.9)	7 (36.8)
Primary site, n (%)			0.000	1.000
Stomach	14 (77.8)	15 (78.9)
Cardia	44 (22.2)	4 (21.1)
Liver metastasis, n (%)			0.222	0.638
Yes	10 (55.6)	12 (63.2)
No	8 (44.4)	7 (36.8)
Smoking history, n (%)			0.703	0.402
Yes	7 (38.9)	10 (52.6)
No	11 (61.1)	9 (47.4)
Drinking history, n (%)			1.337	0.248
Yes	7 (38.9)	11 (57.9)
No	11 (61.1)	8 (42.1)
Comorbidities, n (%)			0.000	1.000
Yes	44 (22.2)	4 (21.1)
No	14 (77.8)	15 (78.9)

ECOG: Eastern Cooperative Oncology Group.

Table 2 Occurrence of adverse events in the inetetamab combined with S-1 plus oxaliplatin group and the trastuzumab combined with S-1 plus oxaliplatin group, n (%)

AEs	Inetetamab group (n = 18)		Trastuzumab group (n = 19)
	All AEs	≥ Grade 3 AE	All AEs	≥ Grade 3 AE
Leukopenia	15 (83)	4 (22)	15 (79)	3 (16)
Reduction in hemoglobin	11 (61)	0	10 (53)	1 (5)
Thrombocytopenia	4 (22)	1 (6)	7 (37)	1 (5)
Nausea	15 (83)	4 (22)	16 (84)	2 (11)
Vomiting	7 (39)	0	5 (26)	1 (5)
Diarrhea	2 (11)	0	2 (11)	0
Anorexia	11 (61)	1 (6)	6 (32)	1 (5)
Abnormal liver function	3 (17)	0	3 (16)	0
Cardiotoxicity	1 (6)	0	2 (11)	0
Numbness in hands and feet	3 (17)	0	2 (11)	0
Allergic reaction	1 (6)	0	0	0
Fever	0	0	2 (11)	0

AEs: Adverse events.